Abstract
To follow the biodistribution of exogenous hyaluronan in tumor-bearing animals, a total of seventeen inbred rats with hepatic metastases from a colonic adenocarcinoma received 125I-labelled hyaluronan by intravenous injections. Group I received only labeled hyaluronan (25 μg), whereas group II received 2.5 mg chondroitin sulphate prior to labeled hyaluronan, to block receptor uptake in normal liver endothelial cells. Animals in group III received intravenous, as well as intraperitoneal chondroitin sulphate (2.5 mg), to see if a better and prolonged blocking could be achieved. Radioactivity was visualized by whole body autoradiography, using phosphorimaging and the average radioactivity determined as phosphoimaging density units of the total area of hepatic metastases, normal liver, and skeletal muscle by computer-based image analysis. At 5 h, tumors in groups II and III showed higher uptake (4.8 ±1.8, P = .01 and 3.6 ±1.1, P = .01, respectively), in comparison to group I (1.8 ±0.6), and the mean normal liver/tumor concentration ratio was reduced from 21.4 ±10.1 in group I to 5.7 ±2.7 in group II and 3.5 ±1.1 in group III (P = .008 and P = .01, respectively).
Our study shows that hyaluronan targets liver metastases of a colon adenocarcinoma. Furthermore, chondroitin sulphate pretreatment increases tumor uptake, while uptake at normal receptor sites is significantly reduced. The results also suggest that after blocking of normal hyaluronan/chondroitin sulphate receptors in healthy tissue, hyaluronan may be used to deliver drugs to specific hyaluronan receptor-positive sites of pathology.
Similar content being viewed by others
References
Gilbert JM, Jeffrey I, Evans M, Kark AE (1984) Br J Surg 71: 203–5.
Köhne-Wömpner CH, Schmoll HJ, Harstrick A, Rustum YM (1992) Semin Oncol 19: 105–25.
Csóka K, Larsson R, Tholander B, Gerdin E, de la Torre M, Nygren P (1994) Gynecol Oncol 54: 163–70.
Jain RK (1988) Cancer Res 48: 2641–58.
Jain RK (1994) Sci Amer: 58–65.
Laurent TC, Fraser JRE (1992) FASEB J 8: 2397–404.
Gustafson S, Björkman T. (1997) Glycoconjugate J 14: 561–8.
Gustafson S (1997). In The Chemistry, Biology and Medical Applications of Hyaluronan and Its Derivatives (Laurent TC ed). London Portland Press.
Gustafson S, Björkman T, Forsberg N, Lind T, Wikström T, Lidholt K (1995) Glycoconjugate J 12: 350–5.
Gustafson S, Björkman T, Wikström T, McCourt P, Forsberg N, Graf W (1995) Targeting of hyaluronan to tumours via binding to ICAM-1. In “3rd International Workshop on Hyaluronan in Drug Delivery.” Royal Soc Med Press, Round Table Series 40 pp 1–9.
Samuelsson C. Gustafson S (1997) Glycoconjugate J 15: 169–75.
Steele G Jr, Sjögren HO (1974) Cancer Res 34: 1801–7.
Lebel L, Smith L, Risberg B, Laurent TC, Gerdin B (1989) Am J Physiol 256: 1524–31.
Gustafson S, Björkman T, Westlin J-E (1994) Glycoconjugate J 11: 608–13.
Gustafson S (1997) Glycobiology 7: 1209–14.
Graf W, Sundin A, Glimelius B, Ahlström H, Carlsson J (1992) Eur J Surg Oncol 18: 608–14.
Ullberg S, Larsson B, Tjälve H (1982) Autoradiography. In Biologic Applications of Radiotracers (Glenn HJ ed) pp 55–108. Boca Raton, Fl.; CRC Press, Inc.
Dencker L, Larsson B, d'Argy R, Ullberg S, Tjälve H (1991) Pure Appl Chem 63: 1271–7.
Gustafson S, Björkman T (1997) J Pharm Pharmacol 49: 29.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mahteme, H., Graf, W., Larsson, B. et al. Uptake of hyaluronan in hepatic metastases after blocking of liver endothelial cell receptors. Glycoconj J 15, 935–939 (1998). https://doi.org/10.1023/A:1006923402807
Issue Date:
DOI: https://doi.org/10.1023/A:1006923402807